SCHEMBL1047448

SCHEMBL1047448

O=c1[nH]cc(-c2c(Cl)cccc2Cl)c2ccnc(Nc3ccc(N4CCOCC4)cc3)c12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ZAP70 P43403 6/20 0.54
FGFR1 P11362 2/20 0.48
SRC P12931 2/20 0.48
PKMYT1 Q99640 2/20 0.48
PDGFRB P09619 1/20 0.48
SLC2A1 P11166 1/20 0.48
PDGFRA P16234 1/20 0.48
ROCK1 Q13464 1/20 0.44
AURKA O14965 1/20 0.44
AURKB Q96GD4 1/20 0.44
TTBK1 Q5TCY1 1/20 0.44
TTBK2 Q6IQ55 1/20 0.44
WEE1 P30291 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PDE2A O00408 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1049469 0.92 ZAP70 (0.59) ZAP70ROCK1AURKAAURKBTTBK1
SCHEMBL1048404 0.90 ZAP70 (0.51) ZAP70FGFR1SRCPKMYT1PDGFRB
SCHEMBL1048699 0.89 ZAP70 (0.54) ZAP70ROCK1TTBK1TTBK2KDM4E
SCHEMBL1047617 0.87 ZAP70 (0.54) ZAP70SRCROCK1TTBK1TTBK2
SCHEMBL1049307 0.87 ZAP70 (0.56) ZAP70ROCK1TTBK1TTBK2MAPT
SCHEMBL1049855 0.82 ZAP70 (0.49) ZAP70ROCK1KDM4EMEN1MAPT
SCHEMBL1047996 0.82 ITK (0.54) ZAP70ROCK1MAPTSMN1; SMN2
SCHEMBL1049683 0.81 ZAP70 (0.76) ZAP70ROCK1TTBK1TTBK2MAPK10
SCHEMBL1046783 0.81 KDR (0.54) ZAP70SRCROCK1KDM4EMAPT
SCHEMBL1043457 0.81 ZAP70 (0.52) ZAP70ROCK1TTBK1TTBK2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US claimed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US claimed
EP-2238137-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-10-13 EP claimed
WO-2009097287-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2009-08-06 WO claimed
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US disclosed
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US disclosed
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US disclosed
CN-101990539-A Compounds and compositions as kinase inhibitors IRM LLC 2011-03-23 CN disclosed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US disclosed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US disclosed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US disclosed
EP-2238137-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-10-13 EP disclosed
WO-2009097287-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2009-08-06 WO disclosed
WO-2009097287-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2009-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FYN, SYK, RET ZAP70 4/4885FGFR1 38/4885SRC 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.